Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2020 / Cilt: 54 - Sayı: 2

Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings

Pages
159–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The TNM staging system of the American Joint Committee on Cancer (AJCC) was developed to predictthe prognosis, based on the specific anatomical features of the primary tumor and the occurrence of metastasis.Keywords: Catecholamine synthesis and metabolism; paraganglioma; pheochromocytoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors.
📊
Key Findings & Data:The incidence of PCC and PGL ranges between 2 and 8 per million, with a prevalencebetween 1:2500 and 1:6500.
💡
Conclusion & Impact:The TNM staging system of the American Joint Committee on Cancer (AJCC) was developed to predictthe prognosis, based on the specific anatomical features of the primary tumor and the occurrence of metastasis.Keywords: Catecholamine synthesis and metabolism; paraganglioma; pheochromocytoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors. Pheochromocytomas arise from chromaffincells in the adrenal medulla, and PGLs arise from chromaffin cells in the ganglia of the autonomic nervous system. Paragangliomasoriginate from sympathetic or parasympathetic ganglia in the abdomen, thorax, and pelvis. The majority of PCC andsympathetic PGL are endocrine active tumors causing clinical symptoms by secreting excess catecholamines (norepinephrine,epinephrine, dopamine) and their metabolites. The incidence of PCC and PGL ranges between 2 and 8 per million, with a prevalencebetween 1:2500 and 1:6500. It peaks between the 3rd and 5th decades of life, and approximately 20% of cases are pediatricpatients. The prevalence among patients with hypertension in outpatient clinic ranges between 0.1-0.6% in adults and between2-4.5% in the pediatric age group. 10-49% of these tumors is detected incidentally in imaging techniques performed for other reasons.However, 4-8% of adrenal incidentalomas are PCCs. Of these neuroendocrine tumors, 80-85% are PCCs and 15-20% are PGLs.Up to 40% of patients with PCC and PGL has disease-specific germline mutations and the situation is hereditary. Of 60% of theremaining sporadic patients, at least 1/3 has a somatic mutation in predisposing genes. 8% of the sporadic cases, 20-75% of the hereditarycases, 5% of the bilateral, adrenal cases, and 33% of the extra-adrenal cases at first presentation are metastatic. AlthoughPCCs and PGLs have scoring systems for histological evaluation of the primary tumor, it is not possible to diagnose whether thetumor is malignant since there is no histological system approved for the biological aggressiveness of this tumor group. Metastasisis defined as the presence of chromaffin tissue in non-chromaffin organs, such as lymph nodes, liver, lungs and bone. Althoughmost of the PCC and PGL are benign, the metastatic disease may develop in 15-17%. Metastatic disease is reported between 2-25%in PCCs and 2.4-60% in PGLs. The TNM staging system of the American Joint Committee on Cancer (AJCC) was developed to predictthe prognosis, based on the specific anatomical features of the primary tumor and the occurrence of metastasis.Keywords: Catecholamine synthesis and metabolism; paraganglioma; pheochromocytoma.

🔖

Cite This Article

AYGÜN, N., ULUDAĞ, M. (2020). Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 54 - Sayı: 2, 159–168. https://ajindex.com/articles/363406

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tevosian SG, Ghayee HK. Pheochromocytomas and Paragangliomas. Endocrinol Metab Clin North Am 2019;48:727–50
  2. Patel D, Phay JE, Yen TWF, Dickson PV, Wang TS, Garcia R, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol 2020;27:1329–37
  3. Schreiner F, Beuschlein F. Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies. Best Pract Res Clin Endocrinol Metab 2019 Oct 21 [Epub ahead of print], doi: 10.1016/j.beem.2019.101347
  4. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
  5. Kiernan CM, Solórzano CC. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment. Surg Oncol Clin N Am 2016;25:119–38
  6. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid can-cer. Pancreas 2010;39:775–83
  7. Crona J, Taïeb D, Pacak K. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocr Rev 2017;38:489–515
  8. Bholah R, Bunchman TE. Review of Pediatric Pheochromocytoma and Paraganglioma. Front Pediatr 2017;5:155
  9. Lam AK. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol 2017;28:213–27
  10. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 2015;11:101–11
  11. Graham JB. Pheochromocytoma and hypertension; an analysis of 207 cases. Int Abstr Surg 1951;92:105–21
  12. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2001;2:297– 311
  13. Cisco RM, Grondal S, Hamberger B. Adrenal physiology. In: Clark OH, Duh QY, Kebebew E, Gosnell JE, Shen WT, editors. Textbook of Endocrine Surgery. 3rd ed. Jaypee Brothers Medical Publishers: 2016. p. 973–8
  14. Lal G, Clark OH. Thyroid, parathyroid and adrenal. In: Brunuca